Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity.

Isabel H Gonzalez-BoccoKatherine BeluchAlyssa ChoChloe LahoudFabiola A ReyesDimitrios G MoshovitisGillian M Unger-MochrieWei WangSarah P HammondJennifer Manne-GoehlerSophia Koo

Published in: Pilot and feasibility studies (2023)

ClinicalTrials.gov Identifier: NCT05210101.

Keyphrases

sars cov
immune response
open label
respiratory syndrome coronavirus
intensive care unit
double blind